AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Charles River Laboratories Invests in Resero Analytics™

May 16, 2019

WILMINGTON, Mass.--(BUSINESS WIRE)--May 16, 2019--

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has invested in Resero Analytics™, a software company focused on providing solutions to the biopharmaceutical industry to harness its data.

As part of its investment, Charles River will collaborate with Resero Analytics and is now the exclusive contract research organization (CRO) partner for TurboToxicology™, a report generation tool that enables faster delivery of high-quality reports.

TurboToxicology: Fast & Accurate Reports

TurboToxicology analyzes nonclinical data in Standard for Exchange of Nonclinical Data (SEND) and other structured data formats, and conducts statistical analyses, applies proprietary algorithms, and displays study results via visually appealing user interfaces. The tool then formats the data, in concert with the scientist’s interpretation, to generate a complete written report that is inclusive of text, tables, figures, and legends.

TurboToxicology enables the efficient production of consistent formatted reports, helping to accelerate this step in the drug development process and thereby accelerating Investigational New Drug (IND) or New Drug Approval (NDA) submissions.

Leveraging Standardized Data

SEND is an implementation of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM) that provides a framework for the standardized, electronic representation of individual research model study data. SEND is intended to increase the effectiveness and efficiency of data review for regulatory submissions.

Leveraging structured data, including SEND, allows TurboToxicology to expedite interpretation and ensure consistency across authors and sites producing toxicology reports, while enabling sponsor companies to make quicker decisions by providing robust data early in the reporting process. This time savings is essential as sponsor companies work to move potential therapeutics through the drug development pipeline efficiently, without sacrificing quality.

Approved Quotes

  • “By implementing solutions that increase efficiency in reporting, our goal is to give our clients the gift of time. By alleviating some of the upfront administrative work, TurboToxicology’s report generation tool will allow time for greater focus on other areas of drug development.” – Birgit Girshick, Corporate Executive Vice President, Discovery & Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services at Charles River
  • “With a global network, and the most robust portfolio in preclinical research, Charles River was the clear CRO partner of choice for TurboToxicology.” – Dave Watson, PhD, MBA, Founder & CEO at Resero Analytics

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

About Resero Analytics

Resero Analytics creates data and software solutions for Pharma, CROs, and Regulators. Our platform improves the quality and timeliness of toxicology data analysis, interpretation, and reporting. We automate tasks that are done manually throughout the industry and help clients make the final call. To learn more, visit reseroanalytics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190516005233/en/

CONTACT: Investor Contact:

Todd Spencer

Corporate Vice President, Investor Relations

781-222-6455

todd.spencer@crl.comMedia Contact:

Amy Cianciaruso

Corporate Vice President, Public Relations

781-222-6168

amy.cianciaruso@crl.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL RESEARCH SCIENCE GENERAL HEALTH

SOURCE: Charles River Laboratories International, Inc.

Copyright Business Wire 2019.

PUB: 05/16/2019 08:00 AM/DISC: 05/16/2019 08:01 AM

http://www.businesswire.com/news/home/20190516005233/en